Oncoloxía médica

2017

1. A PAM50-based chemoendocrine score for hormone receptor-positive breast cancer with an intermediate risk of relapse

   Clinical Cancer Research, Vol. 23, Núm. 12, pp. 3035-3044

2. A consensus statement on the gender perspective in lung cancer

   Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 527-535

3. A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)

   Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624

4. A high-resolution map of transcriptional repression

   eLife, Vol. 6

5. A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study

   Oncotarget, Vol. 8, Núm. 42, pp. 73144-73153

6. A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN)

   Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 28, Núm. 7, pp. 1517-1522

7. Anatomical variations of the greater palatine canal in cone-beam computed tomography

   Surgical and Radiologic Anatomy, Vol. 39, Núm. 7, pp. 717-723

8. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: A multi-institution correlative biomarker study

   Annals of Oncology, Vol. 28, Núm. 7, pp. 1-9

9. Anti-folate receptor-α IgE but not IgG recruits macrophages to attack tumors via TNFa/MCP-1 signaling

   Cancer Research, Vol. 77, Núm. 5, pp. 1127-1141

10. Assessment of HER2 status in resected gastric cancer in European population

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 28, pp. iii15

11. Breast cancer chemoprevention: What and when?

    Cancer and Chemotherapy Reviews, Vol. 12, Núm. 2, pp. 46-57

12. Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma

    International Journal of Cancer, Vol. 140, Núm. 7, pp. 1551-1563

13. Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: The necessity of repeated molecular analysis

    Translational Lung Cancer Research, Vol. 6, pp. S21-S34

14. Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain

    Clinical and Translational Oncology, Vol. 19, Núm. 6, pp. 667-681

15. Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature

    Lung Cancer, Vol. 108, pp. 217-221

16. ERAP1 and HLA-C interaction in inflammatory bowel disease in the Spanish population

    Innate Immunity, Vol. 23, Núm. 5, pp. 476-481

17. Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database

    Clinical and Translational Oncology, Vol. 19, Núm. 12, pp. 1537-1542

18. Epistasis, physical capacity-related genes and exceptional longevity: FNDC5 gene interactions with candidate genes FOXOA3 and APOE

    BMC Genomics, Vol. 18

19. Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions

    Clinical and Translational Oncology, Vol. 19, Núm. 3, pp. 341-356

20. Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study

    Clinical and Translational Oncology, Vol. 19, Núm. 1, pp. 91-104